UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 LAVA Therapeutics N.V. , an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific. | February 6, 2023
13.09.2022 - Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track to report additional clinical data in fourth .
LAVA Therapeutics (LVTX) Highlights Encouraging Clinical Updates on LAVA-051 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.